Prevalence of high-grade HPV types among women in Astana, Kazakhstan (2018-2022)

Abstract

Background: Cervical cancer is a significant public health concern worldwide, and human papillomavirus (HPV) is the leading cause of this disease. While there have been some studies on the prevalence of HPV in Kazakhstan, the country faces unique challenges in preventing and treating HPV-related diseases, including limited resources, a lack of awareness about HPV, and cultural attitudes toward sexual health. This research article aims to provide a comprehensive overview of HPV genotype distribution in Astana, Kazakhstan, for the last five years.

Methods: A cross-sectional study was performed from 2018 to 2022. Study population: Kazakhstani women referring to “Olympus laboratories network” settings for HPV testing age 18-64. AmpliSens® Real-Time PCR kits for HPV genotyping 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) were performed.

Results: This study revealed the increasing trend in HR-HPV prevalence among women for five sequential year periods. As a result, approximately 43% of women referred to the HPV testing were HR-HPV positive, with the most prevalent type being HPV 16 (20%), followed by HPV types 31, 52, 51.

Conclusion: By examining the latest research on HPV and cervical cancer in Kazakhstan, we hope to contribute to developing effective public health policies and interventions to help reduce these diseases' burden in this country. Furthermore, the database will be established for future large-scale studies after vaccination implementation.

Keywords

Human papillomavirus / prevalence / genotype / cervical cancer

References

[1] Arbyn M,Bruni L.Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.Lancet Glob Health2020;8:e191-203 PMCID:PMC7025157

[2] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[3] World Health Organization (WHO). Global health estimates: life expectancy and leading causes of death and disability. WHO; 2020. Accessed from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates [Last accessed on 6 Sep 2023].

[4] Choi S,Pappas-Gogos G.HPV and cervical cancer: a review of epidemiology and screening uptake in the UK.Pathogens2023;12:298 PMCID:PMC9960303

[5] Aimagambetova G.Epidemiology of HPV infection and HPV-related cancers in kazakhstan: a review.Asian Pac J Cancer Prev2018;19:1175-80 PMCID:PMC6031825

[6] Brisson M,Canfell K.Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.Lancet2020;395:575-90 PMCID:PMC7043009

[7] Bruni L,Serrano B. Human papillomavirus and related diseases in Kazakhstan. Summary report. Inf Cent HPV Cancer 2019. Available from: https://hpvcentre.net/statistics/reports/KAZ.pdf [Last accessed on 6 Sep 2023]

[8] Bruni L,Serrano B. ICO/IARC information centre on HPV and cancer (HPV information centre). Human papillomavirus and related diseases in the world. Summary report 10 March 2023. Available from: https://hpvcentre.net/statistics/reports/XWX.pdf [Last accessed on 6 Sep 2023]

[9] Aimagambetova G,Ukybassova T.Cervical cancer screening and prevention in Kazakhstan and central Asia.J Med Screen2021;28:48-50

[10] Saraiya M,Thompson TD.HPV Typing of Cancers WorkgroupUS assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.J Natl Cancer Inst2015;107:djv086 PMCID:PMC4838063

[11] Serrano B,Bosch FX.Epidemiology and burden of HPV-related disease.Best Pract Res Clin Obstet Gynaecol2018;47:14-26

[12] zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50. Available from: https://www.nature.com/articles/nrc798 [Last accessed on 24 Aug 2023] Nat Rev Cancer

[13] Chan CK,Ukybassova T,Azizan A.Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination-review of current perspectives.J Oncol2019;2019:3257939 PMCID:PMC6811952

[14] Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM; New Mexico HPV Pap Registry Steering Committee. Role of HPV genotype, multiple infections, and viral load on the risk of high-grade cervical neoplasia.Cancer Epidemiol Biomarkers Prev2019;28:1816-24 PMCID:PMC8394698

[15] Aimagambetova G,Issanov A.The distribution and prevalence of high-risk HPV genotypes other than HPV-16 and HPV-18 among women attending gynecologists’ offices in Kazakhstan.Biology2021;10:794 PMCID:PMC8389608

[16] Fowler JR,Dunton CJ. Cervical cancer. In: StatPearls. Treasure Island, FL: StatPearls; 2022.

[17] Kombe Kombe AJ,Zahid A.Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation.Front Public Health2020;8:552028 PMCID:PMC7855977

[18] Li X,Dai J.Prevalence of cervicovaginal human papillomavirus infection and genotype distribution in Shanghai, China.Virol J2022;19:146 PMCID:PMC9465878

[19] de Sanjose S, Quint WG, Alemany L, et al.; Retrospective international survey and HPV time trends study group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.Lancet Oncol2010;11:1048-56

[20] Bekmukhambetov YZ,Jarkenov TA,Mukashev TZ. Distribution of high risk human papillomavirus types in western Kazakhstan - retrospective analysis of PCR data. Asian Pac J Cancer Prev 2016;17:2667-72. Available from: https://journal.waocp.org/article_32456.html [Last accessed on 24 Aug 2023]

[21] Niyazmetova L,Stambekova N,Z ,Ali S.Application of molecular genotyping to determine prevalence of HPV strains in pap smears of Kazakhstan women.Int J Infect Dis2017;54:85-8

[22] Aimagambetova G,Ukybassova T,Balykov A,Azizan A.Cervical cancer screening and prevention in Kazakhstan and central Asia.J Med Screen2020;28:48-50

[23] Bolatbekova R,Dushimova Z.Prevalence of HPV and cytological abnormalities in young women in Almaty, Kazakhstan.J Clin Oncol2022;40:e22503

[24] Babi A,Issanov A.Prevalence of high-risk human papillomavirus infection among Kazakhstani women attending gynecological outpatient clinics.Int J Infect Dis2021;109:8-16

[25] Balmagambetova S,Koyshybaev A.Cervical screening in western Kazakhstan: liquid-based cytology "cell scan" versus azur-eosin staining.J Med Screen2020;27:90-5 PMCID:PMC7433700

[26] Vinodhini K,Das BC.Prevalence and risk factors of HPV infection among women from various provinces of the world.Arch Gynecol Obstet2012;285:771-7

[27] Guo J,Dong S.Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: a meta-analysis.Front Public Health2023;11:1128717 PMCID:PMC9982050

[28] Nah EH,Kim S.Human papillomavirus genotype distribution among 18,815 women in 13 Korean cities and relationship with cervical cytology findings.Ann Lab Med2017;37:426-33 PMCID:PMC5500742

[29] Bao YP, Li N, Smith JS, Qiao YL; ACCPAB members. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 2008;18:71-9. Available from: https://ijgc.bmj.com/content/18/1/71.abstract [Last accessed on 8 Sep 2023]

[30] Ren X,Wu B.Efficacy of prophylactic human papillomavirus vaccines on cervical cancer among the Asian population: a meta-analysis.Front Microbiol2022;13:1052324 PMCID:PMC9755181

[31] Liao L,Zeng F,Ding Y.Prevalence and distribution of human papillomavirus genotypes among women with high-grade squamous intraepithelial lesion and invasive cervical cancer in Ganzhou, China.J Clin Lab Anal2019;33:e22708 PMCID:PMC6818556

[32] Kim MA,Kim JH.Current status of human papillomavirus infection and introduction of vaccination to the national immunization program in Korea: an overview.J Korean Med Sci2018;33:e331 PMCID:PMC6300657

[33] Liu Y,Wu H.Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: analysis of results from China's top 3 hospital, 2009-2019.Virol J2020;17:104 PMCID:PMC7359485

[34] Li L,Li T.Absolute risk and attributable fraction of type-specific human papillomavirus in cervical cancer and precancerous lesions-a population-based study of 6286 women in rural areas of China.J Clin Med2022;11:6483 PMCID:PMC9655002

[35] Xia C,Long T,Chan PKS.Current updates on cancer-causing types of human papillomaviruses (HPVs) in east, southeast, and south Asia.Cancers2021;13:2691 PMCID:PMC8198295

[36] Wang J,Wang K.HPV genotype prevalence and distribution during 2009-2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination.BMC Womens Health2019;19:90 PMCID:PMC6615222

[37] Ebrahimi N,Khosravi G.Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective.Front Immunol2023;14:1150238 PMCID:PMC10227716

[38] Dassi L,Botti C.Detection of human papillomaviruses in the nasopharynx of breastfed infants: new findings and meta-analysis.Viruses2020;12:1119 PMCID:PMC7650825

[39] Isaguliants M,Smirnova O,Apolikhin O.Genetic instability and anti-HPV immune response as drivers of infertility associated with HPV infection.Infect Agent Cancer2021;16:29 PMCID:PMC8111735

[40] Junerbayeva GM,Kulmagambetova AZh. Epidemiology of human papillomavirus in women of Aktobe region. Exploratory analysis of cross-sectional survey data. West Kaz Med J 2015;4:49-52. Available from: https://cyberleninka.ru/article/n/epidemiologiya-virusa-papillomy-cheloveka-u-zhenschin-aktyubinskoy-oblasti/viewer [Last accessed on 6 Sep 2023]

[41] Robadi IA,Ducatman BS.The importance of high-risk human papillomavirus types other than 16 and 18 in cervical neoplasia.Arch Pathol Lab Med2018;142:693-5

[42] Aimagambetova G,Issa T.What factors are associated with attitudes towards HPV vaccination among Kazakhstani women? Exploratory analysis of cross-sectional survey data.Vaccine2022;10:824 PMCID:PMC9146459

[43] Akhatova A,Atageldiyeva K.Prophylactic human papillomavirus vaccination: from the origin to the current state.Vaccine2022;10:1912 PMCID:PMC9696339

[44] Babi A,Issanov A.Knowledge and attitudes of mothers toward HPV vaccination: a cross-sectional study in Kazakhstan.Womens Health2023;19:17455057231172355 PMCID:PMC10192804

[45] Imankulova B,Issa T.Prevalence of precancerous cervical lesions among nonvaccinated kazakhstani women: the national tertiary care hospital screening data (2018).Healthcare2023;11:235 PMCID:PMC9859595

[46] Issanov A,Aimagambetova G.Does vaccination protect against human papillomavirus-related cancers? Preliminary findings from the United States national health and nutrition examination survey (2011 - 2018).Vaccine2022;10:2113 PMCID:PMC9781459

[47] Kakotkin VV,Zadorkina TG.Prevention strategies and early diagnosis of cervical cancer: current state and prospects.Diagnostics2023;13:610 PMCID:PMC9955852